Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.

Study Overview

• Status: Completed
• Conditions: Moderate to Severe Persistent Asthma
• Intervention / Treatment: Drug: CBP-201; Drug: Placebo

Detailed Description

This is a multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy and safety of two dose levels of CBP-201 administered to eligible patients with moderate to severe persistent asthma with Type 2 inflammation compared to placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into a treatment period of 24 weeks and a follow-up period of 8 weeks.

• Study Type: Interventional
• Enrollment (Actual): 322
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Malinda Longphre, PhD; Phone Number: +15105203361; Email: mlongphre@connectpharm.com
• Study Contact Backup: Name: Radha Adivikolanu radivikolanu; Phone Number: +14156106887; Email: radivikolanu@connectpharm.com

Study Locations

• China
  • Anhui
    • Bengbu, Anhui, China, 233000
      • Connect Investigative Site 206
  • Beijing
    • Beijing, Beijing, China, 100029
      • Connect Investigative Site 201
    • Beijing, Beijing, China, 100039
      • Connect Investigative Site 216
    • Beijing, Beijing, China, 100730
      • Connect Investigative Site 209
    • Beijing, Beijing, China, 101100
      • Connect Investigative Site 215
  • Guangdong
    • Guangzhou, Guangdong, China, 510080
      • Connect Investigative Site 203
  • Henan
    • Luoyang, Henan, China, 471003
      • Connect Investigative Site 211
  • Hubei
    • Wuhan, Hubei, China, 430000
      • Connect Investigative Site 213
  • Hunan
    • Changsha, Hunan, China, 410013
      • Connect Investigative Site 202
  • Inner Mongolia
    • Baotou, Inner Mongolia, China, 014000
      • Connect Investigative Site 204
    • Baotou, Inner Mongolia, China, 14010
      • Connect Investigative Site 214
    • Hohhot, Inner Mongolia, China, 010050
      • Connect Investigative Site 210
  • Jiangsu
    • Wuxi, Jiangsu, China, 214023
      • Connect Investigative Site 205
    • Yangzhou, Jiangsu, China, 225007
      • Connect Investigative Site 208
  • Jilin
    • Changchun, Jilin, China, 130021
      • Connect Investigative Site 212
  • Liaoning
    • Shenyang, Liaoning, China, 11004
      • Connect Investigative Site 220
  • Shanghai
    • Shanghai, Shanghai, China, 200025
      • Connect Investigative Site 207
    • Shanghai, Shanghai, China, 200433
      • Connect Investigative Site 218
  • Shanxi
    • Taiyuan, Shanxi, China, 030001
      • Connect Investigative Site 221
    • Taiyuan, Shanxi, China, 030032
      • Connect Investigative Site 222
  • Xinjiang
    • Ürümqi, Xinjiang, China, 830054
      • Connect Investigative Site 224
  • Zhejiang
    • Ningbo, Zhejiang, China, 315046
      • Connect Investigative Site 217
• Hungary
  • Hajdú-Bihar
    • Püspökladány, Hajdú-Bihar, Hungary, 4150
      • Connect Investigative Site 304
  • Vas
    • Szombathely, Vas, Hungary, 9700
      • Connect Investigative Site 303
• Korea, Republic of
  • Gyeonggi
    • Incheon, Gyeonggi, Korea, Republic of, 21565
      • Connect Investigative Site 505
    • Seongnam-si, Gyeonggi, Korea, Republic of, 13496
      • Connect Investigative Site 503
  • Seoul Teugbyeolsi
    • Seoul, Seoul Teugbyeolsi, Korea, Republic of, 03080
      • Connect Investigative Site 501
    • Seoul, Seoul Teugbyeolsi, Korea, Republic of, 03722
      • Connect Investigative Site 502
• Poland
  • Dolnoslaskie
    • Lubin, Dolnoslaskie, Poland, 59-300
      • Connect Investigative Site 403
    • Wrocław, Dolnoslaskie, Poland, 53-301
      • Connect Investigative Site 408
  • Lódzkie
    • Skierniewice, Lódzkie, Poland, 96-100
      • Connect Investigative Site 406
  • Malopolskie
    • Kraków, Malopolskie, Poland, 30-033
      • Connect Investigative Site 402
    • Kraków, Malopolskie, Poland, 31-559
      • Connect Investigative Site 401
  • Podlaskie
    • Białystok, Podlaskie, Poland, 15-010
      • Connect Investigative Site 404
    • Białystok, Podlaskie, Poland, 15-010
      • Connect Investigative Site 405
  • Świętokrzyskie
    • Częstochowa, Świętokrzyskie, Poland, 42-200
      • Connect Investigative Site 410
    • Skarżysko-Kamienna, Świętokrzyskie, Poland, 26-110
      • Connect Investigative Site 407
• United States
  • Arizona
    • Tucson, Arizona, United States, 85704
      • Connect Investigative Site 154
  • California
    • Huntington Beach, California, United States, 92647
      • Connect Investigative Site 109
    • Huntington Beach, California, United States, 92647
      • Connect Investigative Site 143
    • Lancaster, California, United States, 93534
      • Connect Investigative Site 132
    • Mission Viejo, California, United States, 92691
      • Connect Investigative Site 125
    • San Jose, California, United States, 95117
      • Connect Investigative Site 103
  • Florida
    • Hialeah, Florida, United States, 33012
      • Connect Investigative Site 161
    • Hollywood, Florida, United States, 33021
      • Connect Investigative Site 114
    • Leesburg, Florida, United States, 34748
      • Connect Investigative Site 142
    • Miami, Florida, United States, 33126
      • Connect Investigative Site 104
    • Miami, Florida, United States, 33145
      • Connect Investigative Site 166
    • Miami, Florida, United States, 33155
      • Connect Investigative Site 118
    • Miami, Florida, United States, 33155
      • Connect Investigative Site 162
    • Miami, Florida, United States, 33174
      • Connect Investigative Site 163
    • Miami, Florida, United States, 33174
      • Connect Investigative Site 164
    • Miami, Florida, United States, 33176
      • Connect Investigative Site 105
    • Miami Gardens, Florida, United States, 33014
      • Connect Investigative Site 165
    • Miami Lakes, Florida, United States, 33014
      • Connect Investigative Site 110
    • Winter Park, Florida, United States, 32789
      • Connect Investigative Site 123
  • Maine
    • Bangor, Maine, United States, 04401
      • Connect Investigative Site 124
  • Maryland
    • White Marsh, Maryland, United States, 21162
      • Connect Investigative Site 120
  • Michigan
    • West Bloomfield, Michigan, United States, 48322
      • Connect Investigative Site 146
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • Connect Investigative Site 112
  • Nebraska
    • Bellevue, Nebraska, United States, 78759
      • Connect Investigative Site 119
  • Nevada
    • North Las Vegas, Nevada, United States, 89030
      • Connect Investigative Site 144
  • New Jersey
    • Princeton, New Jersey, United States, 08540
      • Connect Investigative Site 111
  • New York
    • Buffalo, New York, United States, 14201
      • Connect Investigative Site 117
    • New York, New York, United States, 10036
      • Connect Investigative Site 153
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27104
      • Connect Investigative Site 122
  • Ohio
    • Cincinnati, Ohio, United States, 45236
      • Connect Investigative Site 136
    • Toledo, Ohio, United States, 43617
      • Connect Investigative Site 147
  • Oklahoma
    • Edmond, Oklahoma, United States, 73034
      • Connect Investigative Site 107
    • Oklahoma City, Oklahoma, United States, 73120
      • Connect Investigative Site 149
  • Rhode Island
    • Warwick, Rhode Island, United States, 02886
      • Connect Investigative Site 129
  • Texas
    • Austin, Texas, United States, 78759
      • Connect Investigative Site 116
    • Boerne, Texas, United States, 78006
      • Connect Investigative Site 102
    • Dallas, Texas, United States, 75231
      • Connect Investigative Site 121
    • El Paso, Texas, United States, 79903
      • Connect Investigative Site 108
    • Katy, Texas, United States, 77450
      • Connect Investigative Site 150

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adult male or female patient aged 18 to 75 years with a physician diagnosis of asthma for a minimum of 12 months, based on the Global Initiative for Asthma (GINA) 2020 Guidelines.

2. Patient is currently receiving treatment with medium to high dose inhaled corticosteroids (ICS) in combination with at least 1 additional reliever/controller for at least 90 days prior to the Screening Visit with a stable dose of ICS at least 28 days prior to the Screening Visit.

   Note:

   • Patients receiving ICS equivalent to ≥ 226 μg fluticasone propionate twice daily or equipotent ICS daily dosage of a maximum of 2000 μg/day fluticasone propionate (or equivalent) in combination with a second reliever/controller (eg, long-acting ß agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], theophylline) are eligible.
   • Patients receiving fluticasone furoate/vilanterol with fluticasone furoate ≥ 200 μg once daily are eligible.
   • Patients receiving budesonide/formoterol with budesonide ≥ 640 μg/day are eligible.
   • Patients requiring a third reliever/controller for their asthma are eligible.
   • Patients requiring maintenance oral corticosteroids (OCS) with a stable dose ≤ 10 mg/day prednisone or equivalent OCS in addition to ICS are eligible; OCS total daily dose must have been stable at least 28 days prior to Screening.
3. Prebronchodilator (trough) forced expiratory volume in the first second of expiration (FEV1) must be 40 to 85% of predicted normal at Screening and predose Baseline.
4. Patients must have ≥ 12% reversibility (and ≥ 200 mL difference) in FEV1 within 15 to 30 minutes after the administration of up to 4 puffs of albuterol/salbutamol at Screening.
5. Blood eosinophil count ≥ 300 cells/μL at Screening.
6. Asthma Control Questionnaire, 6-question (ACQ-6) score ≥ 1.5 at Screening and Baseline.

7. Patient has experienced an asthma exacerbation at least once in the past 12 months, defined here as:

   • Use of physician prescribed systemic corticosteroid [oral or parenteral], or
   • Asthma requiring treatment increase of approximately 4 times the baseline dose of ICS, or
   • Hospitalization or emergency medical care due to asthma.
8. Patient demonstrates acceptable inhaler, peak flow meter, and spirometry techniques during the Screening Period in the opinion of the Investigator.
9. Patient demonstrates at least 70% compliance with usual asthma controller use during Run-in Period, based on their patient diary in the 7 days prior to dosing.
10. Patient demonstrates at least 70% compliance with recording of symptom scores in the patient-reported outcomes (PRO) diary completion during Run-in Period and in their handheld pulmonary function device in the 7 days prior to dosing.
11. Patient is able to understand and willing to sign the informed consent form (ICF).
12. Patient is willing and able to comply with clinic visit schedule and study-related procedures, in the opinion of the Investigator.
13. Male patients and their female partners of child-bearing potential agree to practice adequate and effective forms of contraception through the duration of the study from first dose to 8 weeks after the last dose of study drug.

14. Female patients of childbearing potential who are sexually active with a non-sterilized male partner agree to practice adequate and effective forms of contraception from first dose to 8 weeks after last dose of study drug.

    Exclusion Criteria:

    -

    A patient who meets any of the following criteria will be ineligible to participate in this study:

15. Patient has a current diagnosis of a respiratory disorder other than asthma (eg, active lung infection, chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis) or other disease associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
16. Patient has an acute upper or lower respiratory infection requiring antibiotics or antiviral medication within 30 days prior to the date of informed consent or during the Screening/Run-in Period. Note: Patients must be symptom-free for at least 30 days.

17. Patient experiences ana asthma exacerbation at any time from 1 month prior to the Screening Visit up to and including the Baseline Visit. Exacerbation is defined as:

    • Use of physician prescribed systemic corticosteroid [oral or parenteral], or
    • Asthma requiring treatment increase of approximately 4 times the baseline dose of ICS, or
    • Hospitalization or emergency medical care due to asthma.
18. Current smoker or former smoker with a smoking history of > 10 pack-years. Note: This includes tobacco, marijuana, and vaping products.
19. Patient is undergoing or planning to undergo any elective surgery during the study requiring general anesthesia.
20. Patient has received treatment with any marketed (eg, omalizumab, benralizumab, mepolizumab, reslizumab, dupilumab) or investigational biologic drug for asthma or other diseases within 16 weeks or 5 half-lives prior to randomization, whichever is longer.
21. Patient has received treatment with any investigational nonbiologic drug within 30 days or 5 half-lives prior to randomization, whichever is longer.
22. Patient did not respond favorably to previous dupilumab treatment (e.g. therapy failure or patient experienced an adverse reaction to treatment).
23. Patient has received specific immunotherapy within 3 months prior to randomization. Note: If the patient has received immunotherapy, a 3 month washout period is required following the last dose of immunotherapy.
24. Patient is receiving medications or therapy that are prohibited as concomitant medications.
25. Patient has a known or suspected history of immunosuppression, including history of invasive opportunistic infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, HIV, listeriosis, pneumocystosis, pulmonary non-tuberculosis mycobacteria, or tuberculosis, regardless of infection resolution; or unusually frequent, recurrent, or prolonged infections. Note: Tuberculosis testing will be performed on a country-by-country basis according to local guidelines if required by regulatory authorities or ethics committees (ECs).
26. Patient has positive results at Screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HbsAqHBsAq), or hepatitis C antibody (HbsAqHBsAq) with positive HCV RNA polymerase chain reaction; or positive HIV serology at Screening.
27. Patient has a helminth parasitic infection diagnosed within 24 weeks prior to the date of informed consent that has not been treated with, or has failed to respond to, standard of care therapy.
28. Patient shows evidence of acute or chronic infection requiring treatment with antibacterials, antivirals, antifungals, antiparasitics, or antiprotozoals within 28 days of Screening, or significant viral infections within 28 days of Screening that may not have received antiviral treatment (eg, influenza receiving only symptomatic treatment).
29. Patient receives live (attenuated) vaccinations within 7 days of Screening or plans to receive live (attenuated) vaccinations during the study.
30. Patient has any disorder that is not stable in the opinion of the Investigator and may affect the safety of the patient throughout the study; influence the findings of the studies or their interpretations; or impede the patient's ability to complete the entire duration of study, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment.
31. Patient has any clinically significant abnormal findings in physical examination, vital signs, or safety lab tests during Screening/Run-in Period; or any significant medical history which, in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.
32. Patient is being treated with immunosuppressive therapy or biologic therapy for autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis).
33. Patient has a prolonged corrected QT (QTc) interval (male > 450 milliseconds, female > 470 milliseconds) or tachyarrhythmia.

34. Patient has any of the following laboratory abnormalities at Screening:

    • Eosinophils > 1500 cells/mmE3 or 1.5*10E9/L
    • Platelets < 100000 cells/mmE3 or 100*10E9/L
    • Creatine phosphokinase (CPK) > 10 times the upper limit of normal (ULN)
    • Alanine aminotransferase (ALT) > 2.5 times the ULN
    • Aspartate aminotransferase (AST) ≥ 2.5 times the ULN
    • Bilirubin > 2 times the ULN.
35. Patient has a history of alcohol or drug abuse within 12 months of Screening.
36. Patient has an allergy to L-histidine, trehalose, or Tween (polysorbate) 80 or a history of a systemic hypersensitivity reaction, other than localized injection site reaction, to any biologic drug.
37. Patient has a history of malignancy within 5 years prior to the Baseline Visit, with the following exceptions: patients with a history of completely treated carcinoma in situ of cervix and nonmetastatic squamous or basal cell carcinoma of the skin are allowed.
38. Female patient is pregnant, planning to become pregnant, or is breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CBP-201 Dose 1; CBP-201 Dose 1 subcutaneous (SC) injection.	Drug: CBP-201; CBP-201 subcutaneous (SC) injection.; Other Names: rademikibart
Experimental: CBP-201 Dose 2; CBP-201 Dose 2 subcutaneous (SC) injection.	Drug: CBP-201; CBP-201 subcutaneous (SC) injection.; Other Names: rademikibart
Placebo Comparator: Placebo; Placebo subcutaneous (SC) injection.	Drug: Placebo; Placebo subcutaneous (SC) injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute change in prebronchodilator (trough) forced expiratory volume in the first second of expiration (FEV1)	Absolute change from Baseline in prebronchodilator (trough) FEV1 at Week 12. To assess the efficacy of CBP-201 (Dose 1 and Dose 2) versus placebo in patients with moderate to severe persistent asthma with type 2 inflammation as measured by lung function improvements.	at Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute change in prebronchodilator (trough) FEV1	Absolute change from Baseline in prebronchodilator (trough) FEV1 at Weeks 1, 2, 4, 8 and 24.	at Weeks 1, 2, 4, 8 and 24
Percent change in prebronchodilator (trough) FEV1	Percent change from Baseline in prebronchodilator (trough) FEV1 at Weeks 1, 2, 4, 8, 12 and 24.	at Weeks 1, 2, 4, 8, 12 and 24
Change in other lung function measurements	Change from Baseline in other lung function measurements [percentage predicted FEV1, morning and evening peak expiratory flow (PEF)].	From Baseline to Week 24
Time to severe exacerbation and number of events	Time to severe exacerbation and number of events during the 24 weeks Treatment Period.	From Baseline to Week 24
Proportion of patients with ≥ 1 asthma exacerbation	Proportion of patients with ≥ 1 asthma exacerbation during the 24 weeks Treatment Period.	From Baseline to Week 24
Incidence, type and severity of Adverse Event (AE)	Safety endpoints will be summarized by descriptive statistics and narratives where indicated by severity. Safety will be assessed on basis of AEs reported, including SAEs and AESIs.	From Baseline to Week 32
Pharmacokinetics (Steady-state trough PK profile)	Whole blood for plasma CBP-201 concentrations will be obtained and analyzed.	From Baseline to Week 32

Collaborators and Investigators

• Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.
• Investigators: Study Director: Suzhou Connect, Suzhou Connect Biopharmaceuticals, Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): May 11, 2021
• Primary Completion (Actual): August 5, 2023
• Study Completion (Actual): September 28, 2023

Study Registration Dates

• First Submitted: February 24, 2021
• First Submitted That Met QC Criteria: February 24, 2021
• First Posted (Actual): February 26, 2021

Study Record Updates

• Last Update Posted (Actual): March 29, 2024
• Last Update Submitted That Met QC Criteria: March 27, 2024
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Keywords: Type 2 inflammation
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Inflammation; Asthma
• Other Study ID Numbers: CBP-201-WW002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No